OpenAI has entered into a strategic partnership with Novo Nordisk to apply advanced artificial intelligence across drug discovery, operations and manufacturing. The collaboration aims to accelerate the development of new therapies by analysing complex datasets, identifying promising drug candidates and shortening the time it takes to bring treatments from research to patients.
Beyond research, Novo Nordisk plans to use OpenAI’s technology to improve manufacturing efficiency, supply chain management and broader corporate operations. The partnership also includes a focus on workforce development, with OpenAI helping to enhance AI literacy across the pharma company’s global teams so employees can better integrate these tools into everyday work.
Initial pilot programmes will begin across research and development, commercial and manufacturing functions, with broader deployment expected by the end of the year. Both companies emphasised that the collaboration includes strong safeguards around data protection, human oversight and governance to ensure responsible and compliant use of AI.
The move reflects a wider trend of pharmaceutical companies investing heavily in AI to speed up innovation and improve efficiency. However, the regulatory landscape remains fragmented globally. In the European Union, the EU AI Act is being phased in to govern the development and use of AI systems, while the United States currently relies on a mix of state-level rules and emerging federal frameworks. Other markets, including China, have established stricter national regulations covering data protection, algorithms and medical AI applications.
By integrating AI across its operations, Novo Nordisk aims to strengthen its position in areas such as obesity and diabetes treatment, where demand continues to grow and faster innovation could have a significant impact on patient outcomes.
Click here to read the original news story.